Bridging gaps in haemophilia care: a strategic vision for the UAE

For more than 40 years, Pfizer has remained steadfast in its commitment to improving the lives of people living with haemophilia by championing innovation and forging strategic partnerships.

In the Gulf region, and particularly in the UAE, we are observing significant advancements in haemophilia care driven by national health strategies such as the UAE National Health Agenda 2021. These efforts encompass improved awareness and substantial investment in healthcare infrastructure, collectively redefining patient experience.

Despite these strides, challenges persist. Ensuring equitable access to comprehensive haemophilia treatment across UAE continues to be a priority. The UAE government, along with various healthcare organisations, are actively working to enhance the availability and affordability of these critical treatments.

Haemophilia patients often experience a significant lack of representation in societal and medical discussions, which can lead to a gap in understanding and addressing their unique needs and challenges. This chronic disorder imposes a profound burden not only on patients but also on their caregivers.

Building a strong community support network is essential for empowering individuals and families affected by haemophilia. Support groups, educational workshops, and community events can provide emotional support and enable patients to manage their condition effectively. Incorporating the voices of patients and caregivers into decision-making processes is crucial.

Pfizer Gulf is working closely with local healthcare institutions, regulatory bodies, and professional societies to help address these gaps. Our efforts include supporting physician education, facilitating access to the latest treatment options, collaborating with patient advocacy groups, investing in real-world data generation and raising disease awareness about the burden of haemophilia through collaborative campaigns and scientific exchanges.

Effective policymaking and advocacy are crucial in overcoming these challenges. Collaborative efforts among government bodies, healthcare providers, patient advocacy groups, and international organizations can drive policy changes that improve treatment access, fund research and support comprehensive care models.

Haemophilia remains a complex, but the UAE has made meaningful progress by fostering a healthcare ecosystem that prioritises innovation and public-private collaboration. As therapies evolve, so must our models of care through shifting from reactive to preventative, from product-focused to patient-centered.

At Pfizer Gulf, we are committed to contributing to this transformation, not only through scientific advancement, but also by actively engaging in policy shaping, supporting education, and building enduring partnerships across the region.

Our vision is clear: to close the gaps in haemophilia care, not just with medicine, but with collaboration, compassion, and a commitment to long-term impact.